Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia
To evaluate the efficacy of porcine anti-human lymphocyte globulin (P-ALG) plus cyclosporine A (CsA) therapy for severe aplastic anemia (SAA). Forty-eight SAA patients (31 males, 17 females) including 17 very severe aplastic anemias (vSAA) were treated with ALG plus CsA between 1999 to 2009 in our h...
Gespeichert in:
| Veröffentlicht in: | Zhōnghuá xuèyèxué zázhì 2011-04, Vol.32 (4), p.241-244 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 4 |
| container_start_page | 241 |
| container_title | Zhōnghuá xuèyèxué zázhì |
| container_volume | 32 |
| creator | Han, Bing Yan, Si-yi Zou, Nong Zhang, Wei Li, Jian Duan, Ming-hui Jiao, Li Zhuang, Jun-ling Wang, Shu-jie Zhou, Dao-bin Zhu, Tie-nan Xu, Ying Zhao, Yong-qiang Shen, Ti |
| description | To evaluate the efficacy of porcine anti-human lymphocyte globulin (P-ALG) plus cyclosporine A (CsA) therapy for severe aplastic anemia (SAA).
Forty-eight SAA patients (31 males, 17 females) including 17 very severe aplastic anemias (vSAA) were treated with ALG plus CsA between 1999 to 2009 in our hospital and the outcomes were analyzed retrospectively for early mortality, response rate and quality, survival rate, toxicity and complications.
The median age was 28 (13 - 64) years. The interval from diagnosis to treatment was 45 days. The median neutrophil count at diagnosis was 0.178 × 10(9)/L. Overall response was 83.3% (54.2% complete, 29.2% partial) with a median time of 90 (23 - 380) days. 10.4% died of infection within 30 days mainly of fungi infection. Only 1 patient relapsed 2 years after treatment. No clonal disease was found. The 1.5-year survival rate was 87.5%. vSAAs had less response, higher early mortality and less survival (64.7%, 29.4% and 51.8%, respectively) compared to that of SAA (93.5%, 0, |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_881087348</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>881087348</sourcerecordid><originalsourceid>FETCH-LOGICAL-p125t-44e0b80f55b1cd5c35db98aa324565a95a381c183000981018657ef0c8d3f8483</originalsourceid><addsrcrecordid>eNo1kMtKxDAARbNQnGGcX5DsXBXyaNp0OQy-YEAXupSSpKkNJE3MQ-jfW3Vc3c25h8u9AFtEGK1IS9oN2KdkJGKYNpxSdAU2BLOma1GzBe8vPiozayjmbKqpODFDu7gwebVkDT-sl8WaGQZbElSLsj4FH38KB5gnHUVY4OgjTPpLx9USrEjZqFWnnRHX4HIUNun9OXfg7f7u9fhYnZ4fno6HUxUwYbmqa40kRyNjEquBKcoG2XEhKKlZw0THBOVYYU4RQh3HCPOGtXpEig905DWnO3D75w3Rfxadcu9MUtradYYvqedribf0l7w5k0U6PfQhGifi0v8_Qr8B0khdJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881087348</pqid></control><display><type>article</type><title>Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Han, Bing ; Yan, Si-yi ; Zou, Nong ; Zhang, Wei ; Li, Jian ; Duan, Ming-hui ; Jiao, Li ; Zhuang, Jun-ling ; Wang, Shu-jie ; Zhou, Dao-bin ; Zhu, Tie-nan ; Xu, Ying ; Zhao, Yong-qiang ; Shen, Ti</creator><creatorcontrib>Han, Bing ; Yan, Si-yi ; Zou, Nong ; Zhang, Wei ; Li, Jian ; Duan, Ming-hui ; Jiao, Li ; Zhuang, Jun-ling ; Wang, Shu-jie ; Zhou, Dao-bin ; Zhu, Tie-nan ; Xu, Ying ; Zhao, Yong-qiang ; Shen, Ti</creatorcontrib><description>To evaluate the efficacy of porcine anti-human lymphocyte globulin (P-ALG) plus cyclosporine A (CsA) therapy for severe aplastic anemia (SAA).
Forty-eight SAA patients (31 males, 17 females) including 17 very severe aplastic anemias (vSAA) were treated with ALG plus CsA between 1999 to 2009 in our hospital and the outcomes were analyzed retrospectively for early mortality, response rate and quality, survival rate, toxicity and complications.
The median age was 28 (13 - 64) years. The interval from diagnosis to treatment was 45 days. The median neutrophil count at diagnosis was 0.178 × 10(9)/L. Overall response was 83.3% (54.2% complete, 29.2% partial) with a median time of 90 (23 - 380) days. 10.4% died of infection within 30 days mainly of fungi infection. Only 1 patient relapsed 2 years after treatment. No clonal disease was found. The 1.5-year survival rate was 87.5%. vSAAs had less response, higher early mortality and less survival (64.7%, 29.4% and 51.8%, respectively) compared to that of SAA (93.5%, 0,</description><identifier>ISSN: 0253-2727</identifier><identifier>PMID: 21569706</identifier><language>chi</language><publisher>China</publisher><subject>Adolescent ; Adult ; Anemia, Aplastic - drug therapy ; Animals ; Antilymphocyte Serum - therapeutic use ; Cyclosporine - therapeutic use ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Lymphocytes - immunology ; Male ; Middle Aged ; Retrospective Studies ; Swine ; Treatment Outcome ; Young Adult</subject><ispartof>Zhōnghuá xuèyèxué zázhì, 2011-04, Vol.32 (4), p.241-244</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21569706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Han, Bing</creatorcontrib><creatorcontrib>Yan, Si-yi</creatorcontrib><creatorcontrib>Zou, Nong</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Duan, Ming-hui</creatorcontrib><creatorcontrib>Jiao, Li</creatorcontrib><creatorcontrib>Zhuang, Jun-ling</creatorcontrib><creatorcontrib>Wang, Shu-jie</creatorcontrib><creatorcontrib>Zhou, Dao-bin</creatorcontrib><creatorcontrib>Zhu, Tie-nan</creatorcontrib><creatorcontrib>Xu, Ying</creatorcontrib><creatorcontrib>Zhao, Yong-qiang</creatorcontrib><creatorcontrib>Shen, Ti</creatorcontrib><title>Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia</title><title>Zhōnghuá xuèyèxué zázhì</title><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><description>To evaluate the efficacy of porcine anti-human lymphocyte globulin (P-ALG) plus cyclosporine A (CsA) therapy for severe aplastic anemia (SAA).
Forty-eight SAA patients (31 males, 17 females) including 17 very severe aplastic anemias (vSAA) were treated with ALG plus CsA between 1999 to 2009 in our hospital and the outcomes were analyzed retrospectively for early mortality, response rate and quality, survival rate, toxicity and complications.
The median age was 28 (13 - 64) years. The interval from diagnosis to treatment was 45 days. The median neutrophil count at diagnosis was 0.178 × 10(9)/L. Overall response was 83.3% (54.2% complete, 29.2% partial) with a median time of 90 (23 - 380) days. 10.4% died of infection within 30 days mainly of fungi infection. Only 1 patient relapsed 2 years after treatment. No clonal disease was found. The 1.5-year survival rate was 87.5%. vSAAs had less response, higher early mortality and less survival (64.7%, 29.4% and 51.8%, respectively) compared to that of SAA (93.5%, 0,</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anemia, Aplastic - drug therapy</subject><subject>Animals</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lymphocytes - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Swine</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0253-2727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtKxDAARbNQnGGcX5DsXBXyaNp0OQy-YEAXupSSpKkNJE3MQ-jfW3Vc3c25h8u9AFtEGK1IS9oN2KdkJGKYNpxSdAU2BLOma1GzBe8vPiozayjmbKqpODFDu7gwebVkDT-sl8WaGQZbElSLsj4FH38KB5gnHUVY4OgjTPpLx9USrEjZqFWnnRHX4HIUNun9OXfg7f7u9fhYnZ4fno6HUxUwYbmqa40kRyNjEquBKcoG2XEhKKlZw0THBOVYYU4RQh3HCPOGtXpEig905DWnO3D75w3Rfxadcu9MUtradYYvqedribf0l7w5k0U6PfQhGifi0v8_Qr8B0khdJA</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Han, Bing</creator><creator>Yan, Si-yi</creator><creator>Zou, Nong</creator><creator>Zhang, Wei</creator><creator>Li, Jian</creator><creator>Duan, Ming-hui</creator><creator>Jiao, Li</creator><creator>Zhuang, Jun-ling</creator><creator>Wang, Shu-jie</creator><creator>Zhou, Dao-bin</creator><creator>Zhu, Tie-nan</creator><creator>Xu, Ying</creator><creator>Zhao, Yong-qiang</creator><creator>Shen, Ti</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201104</creationdate><title>Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia</title><author>Han, Bing ; Yan, Si-yi ; Zou, Nong ; Zhang, Wei ; Li, Jian ; Duan, Ming-hui ; Jiao, Li ; Zhuang, Jun-ling ; Wang, Shu-jie ; Zhou, Dao-bin ; Zhu, Tie-nan ; Xu, Ying ; Zhao, Yong-qiang ; Shen, Ti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p125t-44e0b80f55b1cd5c35db98aa324565a95a381c183000981018657ef0c8d3f8483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anemia, Aplastic - drug therapy</topic><topic>Animals</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lymphocytes - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Swine</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Han, Bing</creatorcontrib><creatorcontrib>Yan, Si-yi</creatorcontrib><creatorcontrib>Zou, Nong</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Duan, Ming-hui</creatorcontrib><creatorcontrib>Jiao, Li</creatorcontrib><creatorcontrib>Zhuang, Jun-ling</creatorcontrib><creatorcontrib>Wang, Shu-jie</creatorcontrib><creatorcontrib>Zhou, Dao-bin</creatorcontrib><creatorcontrib>Zhu, Tie-nan</creatorcontrib><creatorcontrib>Xu, Ying</creatorcontrib><creatorcontrib>Zhao, Yong-qiang</creatorcontrib><creatorcontrib>Shen, Ti</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Bing</au><au>Yan, Si-yi</au><au>Zou, Nong</au><au>Zhang, Wei</au><au>Li, Jian</au><au>Duan, Ming-hui</au><au>Jiao, Li</au><au>Zhuang, Jun-ling</au><au>Wang, Shu-jie</au><au>Zhou, Dao-bin</au><au>Zhu, Tie-nan</au><au>Xu, Ying</au><au>Zhao, Yong-qiang</au><au>Shen, Ti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia</atitle><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><date>2011-04</date><risdate>2011</risdate><volume>32</volume><issue>4</issue><spage>241</spage><epage>244</epage><pages>241-244</pages><issn>0253-2727</issn><abstract>To evaluate the efficacy of porcine anti-human lymphocyte globulin (P-ALG) plus cyclosporine A (CsA) therapy for severe aplastic anemia (SAA).
Forty-eight SAA patients (31 males, 17 females) including 17 very severe aplastic anemias (vSAA) were treated with ALG plus CsA between 1999 to 2009 in our hospital and the outcomes were analyzed retrospectively for early mortality, response rate and quality, survival rate, toxicity and complications.
The median age was 28 (13 - 64) years. The interval from diagnosis to treatment was 45 days. The median neutrophil count at diagnosis was 0.178 × 10(9)/L. Overall response was 83.3% (54.2% complete, 29.2% partial) with a median time of 90 (23 - 380) days. 10.4% died of infection within 30 days mainly of fungi infection. Only 1 patient relapsed 2 years after treatment. No clonal disease was found. The 1.5-year survival rate was 87.5%. vSAAs had less response, higher early mortality and less survival (64.7%, 29.4% and 51.8%, respectively) compared to that of SAA (93.5%, 0,</abstract><cop>China</cop><pmid>21569706</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-2727 |
| ispartof | Zhōnghuá xuèyèxué zázhì, 2011-04, Vol.32 (4), p.241-244 |
| issn | 0253-2727 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_881087348 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Anemia, Aplastic - drug therapy Animals Antilymphocyte Serum - therapeutic use Cyclosporine - therapeutic use Female Humans Immunosuppressive Agents - therapeutic use Lymphocytes - immunology Male Middle Aged Retrospective Studies Swine Treatment Outcome Young Adult |
| title | Porcine anti-human lymphocyte globulin plus cyclosporine A therapy for severe aplastic anemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A09%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Porcine%20anti-human%20lymphocyte%20globulin%20plus%20cyclosporine%20A%20therapy%20for%20severe%20aplastic%20anemia&rft.jtitle=Zh%C5%8Dnghu%C3%A1%20xu%C3%A8y%C3%A8xu%C3%A9%20z%C3%A1zh%C3%AC&rft.au=Han,%20Bing&rft.date=2011-04&rft.volume=32&rft.issue=4&rft.spage=241&rft.epage=244&rft.pages=241-244&rft.issn=0253-2727&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E881087348%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=881087348&rft_id=info:pmid/21569706&rfr_iscdi=true |